ZYXI:NSD-Zynex Inc (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 7.9

Change

+0.07 (+0.89)%

Market Cap

N/A

Volume

0.07M

Analyst Target

USD 27.35
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

+0.02 (+0.03%)

USD 9.28B
PDCO Patterson Companies Inc

+0.37 (+1.83%)

USD 1.95B
AHG Akso Health Group ADR

+0.02 (+1.82%)

USD 0.27B
EDAP EDAP TMS SA

+0.06 (+2.33%)

USD 0.10B
YI 111 Inc

+0.15 (+16.67%)

USD 0.07B
COSM Cosmos Health Inc.

+0.04 (+5.39%)

N/A

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.46% 71% C- 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.46% 57% F 27% F
Trailing 12 Months  
Capital Gain -2.71% 100% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.71% 100% F 39% F
Trailing 5 Years  
Capital Gain -36.85% 67% D+ 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.85% 67% D+ 27% F
Average Annual (5 Year Horizon)  
Capital Gain 1.41% N/A N/A 46% F
Dividend Return 1.41% N/A N/A 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.06% N/A N/A 42% F
Risk Adjusted Return 3.27% N/A N/A 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike